Can a new pill outsmart resistant prostate cancer?

NCT ID NCT03436485

Ongoing Disease control Sponsor: Orion Corporation, Orion Pharma Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial is testing an experimental oral drug called ODM-208 in men with metastatic castration-resistant prostate cancer, a type of prostate cancer that has spread and no longer responds to standard hormone therapy. The main goal is to find the highest safe dose and to assess the drug's safety and how the body processes it. Participants take ODM-208 daily along with other medications to manage side effects. The study aims to determine if this drug can be a viable treatment option for this challenging condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ODM-208, an oral drug, taken daily with glucocorticoid and fludrocortisone
What this could lead to: If successful, this could lead to a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapies.
What could go wrong: This is an early-phase trial, so the drug may not be effective or may cause significant side effects. The results are preliminary and need further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER METASTATIC

Contacts and locations

Locations

Centre Léon Bérard

Lyon, France
Charing Cross Hospital

London, United Kingdom
Helsinki University Central Hospital

Helsinki, Finland
Hopital Foch

Suresnes, 92150, France
Institut Gustave Roussy

Villejuif, France
Institut de cancérologie Strasbourg Europe

Strasbourg, France
Institute Bergonié

Bordeaux, France
Institute Paoli-Calmettes

Marseille, France
Masonic Cancer Center, University of Minnesota

Minneapolis, Minnesota, 55455, United States
Nebraska Cancer Specialists

Omaha, Nebraska, 68114, United States
Royal Marsden Hospital

London, SW3 6JJ, United Kingdom
Royal Preston Hospital

Preston, PR2 9HT, United Kingdom
Tampere University Hospital

Tampere, Finland
The Beatson West of Scotland Cancer Centre

Glasgow, G12 0YN, United Kingdom
The Christie NHS Foundation Trust

Manchester, United Kingdom
The Rutherford Cancer Centre, North East

Bedlington, United Kingdom
The Rutherford Cancer Centre, North West

Liverpool, United Kingdom
University at Buffalo, Kaleida Health Great Lakes Cancer Care Collaborative

Buffalo, New York, 14203, United States
University of Maryland Marlene and Stewart Greenebaum Cancer Center

Baltimore, Maryland, 21201, United States
Velindre Cancer Centre

Cardiff, CF14 2TL, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.